Lyell Immunopharma, Inc.

Lyell Immunopharma (LYEL) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in our near-term monitoring window. However, low signal in a 90-day window does not indicate low underlying risk; the company's capital structure, financing history, and dilution trajectory require deeper analysis. The full $49 Report extends coverage to 12 months of filing activity, calculates shareholder dilution risk scores, contextualizes all 8-K events, and flags emerging AI-related risk signals relevant to biotech operations. The full $49 Report adds quantified dilution risk scoring, complete 12-month 8-K context, financing runway analysis, and AI operational risk assessment.